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Abstract: Tinnitus is a perception of sound in absence of sound stimulation. Tinnitus in many cases cannot be eliminated 
by conventional medical treatment with drugs or surgery. Some people who begin to notice tinnitus, whether spontaneous 
or induced by noise, trauma or other insult, will experience spontaneous resolution, but many patients will have persistent 
tinnitus. For some of them, tinnitus sensation will be joined by tinnitus suffering, with many adverse effects like anxiety, 
depression and sleep disorders. For these tinnitus sufferers the psychological and acoustic approach proposed by the Tin-
nitus Retraining Therapy and Acoustic Desensitization Protocol may be helpful. Periodically new treatments are sug-
gested like low-frequency repetitive transcranial magnetic stimulation and sequential phase shift sound cancellation treat-
ment based on the frequency and loudness matching of the tinnitus. The aim of this work is to review modern considera-
tions for the treatment of tinnitus. 
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INTRODUCTION 
  Tinnitus is defined as a perception of a sound without an 
external acoustic source. People with tinnitus often describe 
it as a perception of ringing, whistling or buzzing in one or 
both ears. It can be persistent, intermittent, or throbbing, 
depending on the cause. It is important to distinguish be-
tween subjective and objective tinnitus. Subjective tinnitus 
has a neurophysiological origin whereas objective tinnitus 
can be generated from vascular, muscular or respiratory 
sources and also from the temporo-mandibular joint. There 
are many hypotheses to explain the origin of tinnitus even if 
none has yet been proven. Most of the authors consider the 
origin of tinnitus as cochlear (lesions of the ciliated cells of 
the inner ear after acoustic trauma, presbyacusis, sudden 
hearing loss, etc.) and many patients suffer from hearing loss 
not subjectively felt. The central processes, especially anxi-
ety, exacerbate the discomfort and whether or not the tinnitus 
is disturbing, is determined through further central auditory 
processing of the tinnitus “signal” and its psychological vali-
dation. The 10% of the adult population is afflicted by tinni-
tus and in many cases consequential changes in quality of 
life and substantial modifications of behaviour, including 
anxiety, irritability, depression and sleep disturbances are 
reported. The failure of many treatments and drugs in par-
ticular, has led several teams to propose treatments based on 
different concepts. Tinnitus with very similar physical char-
acteristics can be perceived as intolerable by some patients 
but remain insignificant for others. It is difficult to assess the 
consequences of tinnitus on the patients’ quality of life. This 
absence of correlation between physical intensity of tinnitus, 
its acoustic characteristics and reported discomfort led to the 
use of questionnaire-based assessment methods like the Tin-
nitus Handicap Inventory (THI). The THI is a self-
administered questionnaire to evaluate the impact of tinnitus  
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on the quality of life. The development of patient-based out 
come measurements is significantly improving our ability to 
objectify perceived disability and better quantify the impact 
of tinnitus and its effects, which are largely subjective. Epi-
demiologic studies show that anxiety and depression exacer-
bate the discomfort engendered by tinnitus because patients 
develop a conditioned reflex of focusing on the tinnitus. 
  The goal of this study was to review the most recent neu-
rophysiological findings and the new trends in the treatment 
of subjective tinnitus.  
NEUROPHYSIOLOGY OF TINNITUS 
  The current opinion is that tinnitus is a consequence of 
modified neural activity in the central auditory system con-
sequential to a peripheral damage in the auditory structures 
[1]. The pathophysiological mechanism may be a thalamo-
cortical dysrhythmia with a consequent decreased auditory 
stimulation and surrounding brain area hyperactivity, induc-
ing a topographical reorganization [2] Central theories sug-
gest an increased spontaneous activity associated with tinni-
tus in the dorsal cochlear nucleus [3] and the inferior collicu-
lus of the brainstem [4,5] (Fig. 1). 
  The discordant dysfunction theory was proposed by 
Jastreboff [6] in 1990. This theory postulates that when the 
cochlea is damaged by excessive noise, drugs exposure or 
viral infections the outer hair cells (OHC) are damaged first 
and inner hair cells (IHC) later. IHC provide sound transduc-
tion while OHC amplification of sounds within the cochlea. 
Cochlear damage due to acoustic trauma changes the sponta-
neous firing rates of neurons in the dorsal cochlear nucleus 
(DCN) and hyperactivity can be observed in the DCN. The 
DCN, as primary acoustic nucleus and a site of integration of 
acoustic and sensory inputs, can be an important brain centre 
for the generation and modulation of tinnitus [7]. One hy-
pothesis is that normal electrical activity in the auditory sys-
tem becomes pathologically persistent due to persistent 
changes in the synaptic strength between different neurons in New Trends in Tinnitus Management  The Open Neurology Journal, 2011, Volume 5    13 






















Fig. (1). Sites of tinnitus generation in the auditory pathway. OHC 
outer hair cells, IHC inner hair cells. 
 
  A longstanding hypothesis is that tinnitus and hypera-
cusis, are triggered by a distinctive hyperfunction of the 
OHC, originating from reduced or ineffective efferent con-
trol in the auditory pathway. The lack of control subse-
quently leads to altered neural activity in the central auditory 
pathway. This can be verified by registration of distortion 
products of otoacoustic emissions (DPOAE). Electrophysi-
ological recordings in the mammalian auditory system 
showed an increase in neural responsiveness to external 
sound and a reorganisation of the tonotopic map [8]. Ani-
mals exposed to noise trauma show a synchronous neural 
activity in tonotopically reorganized primary auditory cortex 
consequent on hearing loss. Diminished intracortical inhibi-
tion in the reorganized region appears to enable synchronous 
network activity that develops when deafferented neurons 
begin to respond to input via  their lateral connections. In 
humans with tinnitus and hearing loss, this process may gen-
erate a phantom sound that is perceived in accordance with 
the location of the affected neurons in the cortical place map. 
This neural mechanism of tinnitus [9] assumes that the tono-
topic expansion directly causes the phantom sound because 
deafferentation of a portion of the cochlea reduces the input 
to the corresponding portion of the tonotopic map in each 
field. In many cases the area of the cochlea with the largest 
differences between damaged OHC and normal IHC may 
correspond to the slope of hearing loss on the audiogram and 
the perceived pitch of tinnitus [10]. Further studies are nec-
essary to support this neural mechanism of tinnitus. 
  The concept of neurovascular dysfunction and neurode-
generation in patients with subjective idiopathic tinnitus has 
been recently proposed and reported [11]. 
  A biochemical theory was proposed based on the connec-
tions between the IHC and auditory nerve mediated by neu-
rotransmitters. The most common excitatory neurotransmit-
ter is glutamate while the primary inhibitory neurotransmit-
ter is GABA. When IHC are damaged excessive glutamate is 
released with excitotoxicity. 
  Many people receive high doses of salicylate and a re-
lated molecular mechanism in the origin of tinnitus from the 
periphery of the auditory system is actually proposed. Sali-
cylate has neural excitatory effect on the synapses between 
the sensory IHC and the dendrites of the cochlear spiral gan-
glion neurons which express NMDA receptors. Salicylate 
inhibits cochlear cyclooxygenase whith increased levels of 
arachidonate which enables NMDA responses to the gluta-
mate that IHC spontaneously release [12]. More studies on 
neurotransmitters are needed to determine their role in tinni-
tus development.  
  A recent research suggests to investigate all the causes of 
hemodynamic imbalance and autonomic dysregulation 
which could be responsible of a circulatory impairment of 
the labyrinth and consequently of tinnitus [13].  
NEUROIMAGING OF TINNITUS 
  Neuroimaging studies have been used to evidence the 
cortical expansion and reorganization in tinnitus patients and 
the relationship between sensory, cognitive and affective 
systems. In a cross-sectional study of 2193 subjects aged 41-
82 years studied with brain MRI the authors demonstrated 
that cerebral infarctions of the basal ganglia (OR=0.542), 
thalamus (OR=0.441), and pons (OR=0.319) were especially 
associated with tinnitus [14]. In a study a 3D fast imaging 
employing steady-state acquisition (3D-FIESTA) sequence 
was performed in addition to the temporal MR imaging to 
investigate the role of the vascular loop and compression of 
the vestibulocochlear nerve at the cerebellopontine angle in 
patients with unexplained tinnitus. No statistically significant 
differences were found between the patient and control 
groups [15].  
  The key role of inferior colliculus in unilateral subjective 
tinnitus has been demonstrated using fMRI. The response to 
sound in the inferior colliculus was elevated in tinnitus pa-
tients compared with controls without tinnitus [16]. 
  A neuronal activation in the inferior colliculi and audi-
tory cortices of rats during salicylate-induced tinnitus is also 
confirmed in a study conducted using positron emission to-
mography (PET) imaging. These results suggest that mi-
croPET imaging might be used to study the effects of drugs 
to treat tinnitus [17]. Recently Landgrebe et al. described 
structural alterations in the central nervous system detected 
in tinnitus patients by voxel-based morphometry (VBM): 
significant grey matter decreases in the right inferior collicu-
lus and in the left hippocampus confirm the important role of 
the limbic system in the pathophysiology of tinnitus [18].  
DIAGNOSTIC ASSESSMENT 
  Unfortunately all these efforts in understanding tinnitus 
and its treatment have been limited by an inability to objec-14     The Open Neurology Journal, 2011, Volume 5  Fioretti et al. 
tively assess this disorder and its sequelae. Standard audi-
ologic tests include audiometry for pure tones and speech, 
impedence testing, brain auditory evoked potentials (BAEP) 
and otoacoustic emissions (OAE). Pure tone audiometry is 
the standard test used to assess the hearing threshold for the 
frequencies from 125 to 8.000 Hz (to 16.000 Hz in high-
frequency pure tone audiometry). Speech audiometry is use-
ful in setting hearing aids. BAEP are used to study the pa-
thology of the acoustic nerve and to assess the auditory path-
ways up to inferior colliculus before MRI investigation. 
BAEP are suggested in monolateral hearing loss with patho-
logic responses in cochlear damage, traumatic hearing loss or 
nerve compression. OAE are registered by an earplug-like 
device with a microphone which measures the cochlea's re-
sponse to sound. For this reason OAE represent the cochlear 
mechanical activity of OHC and one source of tinnitus may 
be related to dysfunctions in cochlear mechanical activity.  
  Specialized audiometric tests like pitch and loudness 
matching, residual inhibition (RI), minimum masking level 
(MML) and loudness discomfort level (LDL) are used to 
find out the subjective qualities of tinnitus. Pitch and loud-
ness matching may be useful to characterize tinnitus fre-
quency and intensity. MML is the difference between the 
threshold of tinnitus and the lowest intensity to mask the 
tinnitus. RI is measured as partial or full inhibition of tinni-
tus after 60 seconds of application of MML + 10 dB. The 
measurement of LDL is indicated in patients with reduced 
sound tolerance. These psychophysical measurements have a 
limited value due to the variability of tinnitus loudness and 
the poor correlation between tinnitus loudness and tinnitus 
distress but are useful in counseling and monitoring out-
comes. An initial subjective survey of tinnitus characteristics 
specifically analyzed for duration, time of awareness and 
presence of hyperacusis (reported as sound intolerance) is 
strongly recommended. Hyperacusis is defined as abnormal 
increased sound-induced activity within the auditory path-
ways.  
  The use of broadly validated scales allows comparisons 
between patients and even between institutions. Among the 
different tinnitus-specific self-assessment questionnaires, the 
Tinnitus Handicap Inventory (THI) is desirable for its easy 
administration, incorporation of functional as well as emo-
tional subscales, good validity, strong internal consistency 
and test-retest reliabilities. The THI is a 25-item survey that 
provides a total score and 3 subscale (functional, emotional 
and catastrophic). The reliability and validity of the Italian 
version of the Tinnitus Handicap Inventory (THI) is well-
established [19,20].  
NEW TRENDS IN TINNITUS THERAPY 
  Various treatments have been proposed for tinnitus 
therapy with unsuccessful or unproven results. Researches in 
the pathogenesis of tinnitus suggest that several sites are 
involved, from the peripheral to central auditory system 
including the cochlea, neurotransmitters and receptors, ion 
channels [21] . 
Surgical Therapy 
  Cochlear Implant (CI) is a surgically implanted electronic 
device for the standard treatment in patients with severe to 
profound bilateral hearing loss. CI have been noted to reduce 
tinnitus in some patients [22]. The tinnitus is reduced and 
masked when the cochlear implant is switched on. Another 
mechanism of tinnitus improvement may be positive effect 
of the reorganization of the central auditory nervous system 
after restoration of peripheral sensory input [23,24]. Residual 
inhibition has not been regularly demonstrated in sufferers 
having cochlear implants. Some patients also developed 
tinnitus for the first time after the CI has been implanted [25-
27].  
Medications 
  Anti-seizure medications (like gabapentin) [28,29] and 
benzodiazepines (like diazepam, lorazepam, alprazolam) 
[30] activate GABA receptors that will inhibit the continuous 
firing caused by glutamate. Several trials examined the effect 
of gabapentin on tinnitus demonstrating no effect [31]. Bauer 
et al. demonstrated an improvement in patients with tinnitus 
secondary to acoustic trauma treated with gabapentin [32]. 
Benzodiazepines could suppress tinnitus by reducing neural 
activity in the inferior colliculus [33]. These drugs are help-
ful in reducing anxiety and the sound level of tinnitus but 
cause drowsiness and can lead to dependence.  
  Medications that are antagonistic to glutamate and its 
receptor N-methyl-d-aspartate (NMDA) (like caroverine and 
memantine) reduces glutamate-induced continuous firing of 
the neuron but they also have been shown to exhibit hallu-
cinogenic properties [34].  
  Memantine, an antiglutamatergic drug, is not efficacy in 
the treatment of tinnitus [35]. 
 Caroverine  acts as a glutamate antagonist. Denk et al. 
[36] reported variable results in patients with tinnitus treated 
with caroverine. Ehrenberger et al. [37] investigated the ef-
fects of Caroverine on tinnitus patients for several years. 
Initially they had success in 63% of participants using an IV 
infusion of caroverine subsequently they reported a success 
in 50% of patients with Meniere disease and sudden hearing 
loss.  
  Acamprosate has been recently used like a glutamate 
antagonist. A small clinical trial of acamprosate conducted 
on 25 tinnitus patients showed that 87% had some degree of 
relief and nearly 48% had a reduction of more than 50%. 
Many side effects are described (depression, diarrhea, anxi-
ety) and the drowsiness caused by acamprosate itself may 
have contributed to improvement as many tinnitus patients 
have trouble sleeping [38].  
  Ginkgo Biloba Extract, is a powerful glutamate antago-
nist which acts as a strong anti-oxidant within the cochlea, 
helping to minimize damage caused by free radical build-up 
but not proven results are demonstrated in tinnitus treatment.  
  Studies with tricyclic antidepressant agents (amitriptyline 
nortriptyline and trimipramine) and a selective serotonin 
reuptake inhibitor antidepressant (paroxetine) didn’t prove 
the efficacy of these agents in the management of tinnitus 
[39,40]. Neramexane is currently in phase III clinical trials 
for the treatment of subjective tinnitus. 
Physiological Treatments 
Transcranial Magnetic Stimulation 
  A growing number of studies demonstrate reduction of 
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transcranial magnetic stimulation (rTMS). rTMS produces a 
neurostimolation of specific brain regions potentially in-
volved in the pathophysiology of tinnitus. rTMS might rep-
resent a new promising approach for the treatment of tinnitus 
based on the involvement of dysfunctional neuroplastic 
processes in the brain. TMS may modulate the hyperexcita-
bility of neurons in cerebral cortex that is associated with 
some forms of tinnitus. Better results with rTMS have been 
seen in patients with normal hearing and tinnitus of shorter 
duration (< 4 years). The treatment consists in 10 sessions of 
rTMS over the left temporal or left temporoparietal cortex 
within two weeks. rTMS is to avoid in presence of epilepsy, 
pregnancy, cardiac pace-maker, electrical implants. rTMS is 
a non-invasive method which has proven effective in audi-
tory hallucinations [41-45]. Plewnia et al. [46] demonstrated 
a reduction of tinnitus loudness after temporo-parietal PET-
guided low-frequency rTMS in nine patients with chronic 
tinnitus. These results underline the key role of higher-order 
sensory processing in the pathophysiology of chronic tinni-
tus. Marcondes et al. also demonstrated in patients with tin-
nitus a significant reduction of neural activity in the inferior 
temporal cortex measured by SPECT after active rTMS [47]. 
Other Approaches 
Low-Level Laser Therapy 
  Transmeatal, low laser laser therapy (LLLT) is per-
formed with red (630 nm) or near infrared (830 nm) laser 
light applied through the external ear conduct. It was found 
to be useful for the treatment of chronic tinnitus. It has been 
assumed that LLLT is capable of increasing cell prolifera-
tion, synthesis of ATP, promoting the local blood flow in the 
inner ear and activating repair mechanisms in the inner ear 
[48]. Other clinical studies didn’t demonstrate a significant 
efficacy of LLLT in tinnitus treatment [49]. 
Phase-Out Treatment 
  The sequential phase shift sound cancellation treatment is 
recommended for patients with pure tone tinnitus at a con-
stant frequency. A computer program processed a sound, 
based on the frequency and loudness matching of the tinni-
tus, that interferes with the tinnitus and analyzes the ampli-
tude and phase of the background noise so that the tinnitus 
isn’t heard [50]. Vermeire et al. [51] demonstrated positive 
effects in 60% of treated patients. A multicenters study on 
493 patients treated with phase-shift sound wave cancella-
tion for treatment of predominant tone tinnitus reports a re-
duction in tinnitus volume (defined as >/=6 dB) in 49-72 per 
cent of patients [52]. The hypothesis is that using a tinnitus 
patient’s self-assessed pitch and volume wave, shifted se-
quentially 6° for 30 seconds (over 30 minutes), would cancel 
the neuronal complex in the auditory cortex responsible for 
predominant tone tinnitus. Further studies are necessary to 
validate this treatment. 
Neuromonics 
  The Neuromonics tinnitus treatment is designed to inter-
act and desensitize tinnitus disturbance using a customized 
sound therapy in a framework of structured counselling 
[53,54]. The treatment utilizes a spectrally-modified neural 
stimulus in the form of music and noise, customized for each 
individual’s audiometric profile. In a recent study 90% of 
patients reported a reduction in their tinnitus-related distur-
bance of 40% and more and after six months of treatment 
80% of subjects reported a significant improvement of tinni-
tus disturbance [55]. Neuromonics is not actually available 
in Europe but only in Australia and USA.  
  Recent studies have indicated that tinnitus-related activ-
ity leads to changes in tonotopic representation in auditory 
cortex rather than aberrant activity in the periphery. Auditory 
discrimination training (ADT) could partially reverse the 
changes in tonotopic reorganization in the central nervous 
system after a peripheral damage and improve tinnitus 
[56,57].  
Cognitive-Behavioral Therapy (CBT) and Tinnitus   
Retraining Therapy (TRT) 
  The influence attributed to the limbic and autonomic 
nervous systems on how tinnitus is experienced has led to 
the development of techniques of habituation, widely used in 
cognitive-behavioral therapy (CBT) and in Tinnitus Retrain-
ing Therapy (TRT).  
  The aim of CBT is to modify harmful behaviours and 
thoughts by using “deconditioning” techniques. The main 
objectives of CBT to obtain the habituation to tinnitus are 
reducing arousal levels through relaxation therapy and 
changing negative thoughts about tinnitus through cognitive 
therapy. Londero et al. reported that 75% of the patients 
showed improvement on assessment one year after CBT 
ended [58]. Goebel et al. confirm the long-term benefits of 
CBT for tinnitus [59]. Presently, mindfulness meditation 
offers a new psychological treatment for tinnitus patients 
[60]. 
  Several studies have confirmed the usefulness of TRT in 
the management of patients with tinnitus [61-76]. TRT is 
possible and helpful to patients with disabling chronic tinni-
tus. 
  The goal of TRT is to remove the perception of tinnitus 
from the patient’s consciousness by method aimed at ha-
bituation of the reaction with directive counselling and the 
perception of the tinnitus signal with the sound therapy. The 
aim of counselling is to actively change the way the patient 
thinks about tinnitus and reverse the distress produced by 
tinnitus removing the negative association given to the tinni-
tus signal (habituation of the reaction). Wearable low-level 
broadband noise generators are used in sound therapy to fa-
cilitate habituation of perception. They do not produce a 
masking signal but are regulated at the mixing-point to de-
crease the contrast between the tinnitus signal and random 
background activity within the neural pathways. 
CONCLUSION 
  It is difficult to study and treat tinnitus because of the 
lack of objective tools to quantify and measure it. In these 
last years the use of PET/SPECT and functional magnetic 
resonance imaging permit to identify areas of aberrant neural 
activity in the human brain associated with the perception of 
tinnitus. To date, there has been no therapeutically successful 
treatment of tinnitus in terms of medium or long term 
remission. New insights in the neural basis of tinnitus may 
be found with the development of animal models and 
advanced electrophysiological recording techniques to study 
behavioral assessment and therapeutic compounds to treat 
tinnitus. Some authors showed that many patients have 16     The Open Neurology Journal, 2011, Volume 5  Fioretti et al. 
somatic tinnitus whereby movements manipulations of the 
eyes, head, neck, jaw and shoulder can modulate the 
loudness and pitch of their tinnitus [77-82]. These findings 
may underline the involvement of non auditory centers in the 
pathogenesis and regulation of tinnitus. A future goal will be 
to reach the consensus both for patient assessments and for 
outcome measurements. Longer and multi-institutional stud-
ies should confirm this trend towards better cooperation be-
tween research centres.  
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